Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Natural cytotoxicity triggering receptor 3 (NKp30) is an activating receptor expressed on natural killer (NK) cells that plays a major role in NK cell-mediated tumor cell lysis and cytokine responses. It features a single extracellular I-type Ig-like domain with two potential N-linked glycosylation sites involved in ligand binding, a short stalk region, and a transmembrane domain that associates with ITAM adaptor molecules CD3ζ and FCεRIγ via a charged arginine residue. NKp30 recognizes diverse ligands such as B7-H6 (a tumor cell surface protein), BAT3 (a nuclear protein exposed on stressed tumor cells), and others like pp65 from CMV, triggering NK cell cytotoxicity upon engagement. The crystal structure reveals a unique binding mode with B7-H6 involving both front and back β-sheets of NKp30's C-like domain and CDR-like loops of B7-H6's V-like domain, forming a monomeric 1:1 complex with high shape complementarity and predominantly hydrophobic interactions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Natural cytotoxicity triggering receptor 3 (NKp30) (NKp30).